Akebia Therapeutics to Present at H.C. Wainwright Global Investment Conference

Akebia Therapeutics to Present at H.C. Wainwright Global Investment Conference

September 06, 2023 | Last Trade: US$1.79 0.03 -1.65

CAMBRIDGE, Mass., Sept. 6, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the H.C. Wainwright 25^th Annual Global Investment Conference on Monday, September 11, 2023 at 9:30 a.m. ET.

The H.C. Wainwright Global Investment Conference will take place September 11-13, 2023, in New York.

A webcast of the presentation can be accessed through the Investors section of Akebia's website at https://ir.akebia.com. A replay of the webcast will also be available for approximately 90 days following the conference through the Investors section of Akebia's website at https://ir.akebia.com.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$1.79
Daily Change:	-0.03 -1.65
Daily Volume:	1,139,541
Market Cap:	US$376.420M

November 14, 2024 Akebia Therapeutics: Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease November 12, 2024 Akebia Therapeutics to Present at the Jefferies London Healthcare Conference November 07, 2024 Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights October 22, 2024 Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis October 15, 2024 Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 LOAD MORE NEWS

Featured Stock

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE